March’2020- Development of Olmesartan Intermediate – Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate ; CAS  No. 144689-93-0. Completed lab and pilot scale up studies in March’2020 in collaboration with Shankus Pharma Private Limited Ahmadabad . Pilot sample of the intermediate are put for generation of Holding Time data. Commercial Batches are planned in the month of June’2020.